• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

评估 2019 冠状病毒病大流行期间治疗阿片类药物使用障碍的丁丙诺啡透皮贴剂处方

Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic.

机构信息

Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor.

Department of Economics, Indiana University-Purdue University Indianapolis.

出版信息

JAMA Intern Med. 2021 Apr 1;181(4):562-565. doi: 10.1001/jamainternmed.2020.7497.

DOI:10.1001/jamainternmed.2020.7497
PMID:33346795
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7754073/
Abstract

This cohort study examines changes in the number of buprenorphine prescriptions fill by individuals with opioid use disorder before and during the coronavirus disease 2019 pandemic.

摘要

这项队列研究调查了在 2019 冠状病毒病大流行前后，患有阿片类药物使用障碍的个体的丁丙诺啡处方数量的变化。

相似文献

1
Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic.评估 2019 冠状病毒病大流行期间治疗阿片类药物使用障碍的丁丙诺啡透皮贴剂处方
JAMA Intern Med. 2021 Apr 1;181(4):562-565. doi: 10.1001/jamainternmed.2020.7497.
2
Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US.美国美沙酮处方医生对患者的关注程度。
JAMA. 2021 Jun 1;325(21):2206-2208. doi: 10.1001/jama.2021.4469.
3
Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapy.数据点：接受阿片类激动剂治疗患者苯二氮䓬类药物处方的地区差异
Psychiatr Serv. 2014 Jan 1;65(1):4. doi: 10.1176/appi.ps.650308.
4
Early-Career and Graduating Physicians More Likely to Prescribe Buprenorphine.早期职业医生和即将毕业的医生更有可能开丁丙诺啡处方。
J Am Board Fam Med. 2020 Jan-Feb;33(1):7-8. doi: 10.3122/jabfm.2020.01.190230.
5
Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007-2017.2007 - 2017年美国丁丙诺啡豁免处方医生的增长与分布情况
Ann Intern Med. 2020 Apr 7;172(7):504-506. doi: 10.7326/M19-2403. Epub 2020 Jan 7.
6
Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.COVID-19 大流行期间阿片类药物使用障碍的阿片类镇痛药和丁丙诺啡的处方
JAMA Netw Open. 2021 Apr 1;4(4):e216147. doi: 10.1001/jamanetworkopen.2021.6147.
7
Changes in Outpatient Buprenorphine Dispensing During the COVID-19 Pandemic.新冠疫情期间门诊丁丙诺啡配药的变化。
JAMA. 2020 Dec 15;324(23):2442-2444. doi: 10.1001/jama.2020.22154.
8
Barriers and facilitators for emergency department initiation of buprenorphine: A physician survey.急诊科启动丁丙诺啡治疗的障碍与促进因素：一项医生调查。
Am J Emerg Med. 2019 Sep;37(9):1787-1790. doi: 10.1016/j.ajem.2019.02.025. Epub 2019 Feb 18.
9
Changes in Buprenorphine Prescribing in Community Health Centers.社区卫生中心丁丙诺啡处方的变化
JAMA Health Forum. 2024 Apr 5;5(4):e240634. doi: 10.1001/jamahealthforum.2024.0634.
10
Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage.使用远程医疗为有商业保险或医疗保险优势计划的患者进行丁丙诺啡诱导。
JAMA Netw Open. 2022 Jan 4;5(1):e2142531. doi: 10.1001/jamanetworkopen.2021.42531.

引用本文的文献

1
Trends in Access to Medications for Opioid Use Disorder.阿片类物质使用障碍药物获取趋势。
JAMA Health Forum. 2025 Apr 4;6(4):e250393. doi: 10.1001/jamahealthforum.2025.0393.
2
Associations Between State Policies Facilitating Telehealth and Buprenorphine Episode Initiation and Duration Early in the COVID Pandemic : State Telehealth Policies and Buprenorphine.新冠疫情早期促进远程医疗与丁丙诺啡治疗起始及疗程的州政策之间的关联：州远程医疗政策与丁丙诺啡
J Gen Intern Med. 2024 Nov 14. doi: 10.1007/s11606-024-09188-6.
3
Perceptions of stimulant and buprenorphine diversion and strategies to address it.对兴奋剂和丁丙诺啡转移的认知及应对策略。
Health Aff Sch. 2024 Jun 3;2(6):qxae074. doi: 10.1093/haschl/qxae074. eCollection 2024 Jun.
4
Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022.2012 年至 2022 年联邦政府对华盛顿州丁丙诺啡处方的影响。
Am J Public Health. 2024 Jul;114(7):696-704. doi: 10.2105/AJPH.2024.307649. Epub 2024 May 2.
5
Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial.社区治疗康复干预对持照美沙酮开方医生和美沙酮处方的影响：HC 随机临床试验的预先指定二次分析。
JAMA Netw Open. 2024 Feb 5;7(2):e240132. doi: 10.1001/jamanetworkopen.2024.0132.
6
Real-World Dispensing of Buprenorphine in California during Prepandemic and Pandemic Periods.加利福尼亚州在疫情前和疫情期间丁丙诺啡的实际配药情况。
Healthcare (Basel). 2024 Jan 18;12(2):241. doi: 10.3390/healthcare12020241.
7
Trends in Opioid Use Disorder Outpatient Treatment and Telehealth Utilization Before and During the COVID-19 Pandemic.2019年冠状病毒病大流行之前及期间阿片类物质使用障碍门诊治疗和远程医疗利用情况的趋势
Psychiatr Serv. 2024 Jan 1;75(1):72-75. doi: 10.1176/appi.ps.20230102. Epub 2023 Jul 18.
8
Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs.COVID-19 大流行期间 10 个州医疗补助计划中治疗阿片类药物使用障碍药物的使用趋势。
JAMA Health Forum. 2023 Jun 2;4(6):e231422. doi: 10.1001/jamahealthforum.2023.1422.
9
Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019.阿片类药物使用障碍治疗药物的预先授权限制：2005 年至 2019 年各州法律的趋势。
Ann Med. 2023 Dec;55(1):514-520. doi: 10.1080/07853890.2023.2171107.
10
Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention.COVID 第一年的丁丙诺啡治疗疗程：治疗启动和维持的回顾性研究。
J Gen Intern Med. 2023 Feb;38(3):733-737. doi: 10.1007/s11606-022-07891-w. Epub 2022 Dec 6.